Key Points
Dhoot Transmission listed at ₹1,193.80 on NSE, a 37.06% premium over its ₹871 issue price.
Molbio Diagnostics debuted at ₹980, a 21.44% gain over its ₹807 upper price band.
Dhoot Transmission was subscribed 74.21 times overall, with QIB demand reaching 186.39 times.
Molbio Diagnostics raised ₹939.70 crore and reported 42% revenue growth in FY2026.
Two new NSE IPO listings hit the market on Monday, August 17, 2026. Molbio Diagnostics and Dhoot Transmission both made their stock market debuts today. Dhoot Transmission shares surged 37.06% on the NSE, opening at ₹1,193.80. Molbio Diagnostics listed with a smaller but solid 21.44% premium at ₹980. Both companies had commanded strong grey market premiums ahead of today’s listing.
Dhoot Transmission’s IPO drew heavier demand, subscribed 74.21 times on its final day. Molbio Diagnostics still attracted robust interest, getting subscribed 70.26 times overall.
NSE IPO Debut: How Dhoot Transmission Performed Today
Dhoot Transmission shares opened at ₹1,193.80 on the NSE Monday morning. That represented a strong 37.06% premium over its ₹871 issue price. On the BSE, shares listed even higher, at ₹1,200 per share. Ahead of listing, Dhoot Transmission’s grey market premium stood at ₹258.
Key details behind Dhoot Transmission’s NSE IPO listing:
- Shares debuted at ₹1,193.80 on NSE, a 37.06% listing gain.
- The IPO raised ₹940 crore through this Goa-based company’s offering.
- Overall subscription reached 74.21 times on the final bidding day.
- QIB investors subscribed a massive 186.39 times their reserved portion.
Why Dhoot Transmission’s Listing Beat GMP Expectations
Dhoot Transmission’s pre-listing grey market premium had implied a price near ₹1,129. That estimate suggested a 29.62% gain over the ₹871 issue price. The actual 37.06% listing gain significantly exceeded those grey market expectations. Strong institutional demand likely pushed the debut price higher than anticipated.
Molbio Diagnostics’ NSE IPO Debut Explained
Molbio Diagnostics shares listed at ₹980 on both NSE and BSE on Monday. That marked a 21.44% premium over the company’s ₹807 issue price. The molecular diagnostics firm’s IPO had raised ₹939.70 crore in total. Anchor investors had already committed ₹281.46 crore ahead of the public offering.
Key details behind Molbio Diagnostics’ NSE IPO listing:
- Shares debuted at ₹980, a 21.44% gain over the issue price.
- The IPO comprised a ₹200 crore fresh issue and ₹739.70 crore OFS.
- Overall subscription reached 70.26 times by the final bidding day.
- Molbio’s grey market premium had ranged between ₹50 and ₹220 recently.
Molbio Diagnostics: What the Company Does
Molbio Diagnostics develops portable, battery-operated molecular diagnostic testing platforms. Its proprietary Truenat system delivers PCR-based results within an hour. The company tests for over 30 diseases through 43 diagnostic assays. These include tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV.
Both NSE IPO Listings Show Strong Investor Confidence
Both companies delivered listing-day gains exceeding their pre-market grey premium estimates. That pattern suggests genuine institutional confidence beyond speculative grey market trading alone. Molbio Diagnostics posted FY2026 revenue growth of 42%, with profit up 18%. Strong fundamentals likely supported investor appetite across both offerings today.
Trading details now that both stocks have listed:
- Both stocks trade under the ‘B’ Group of Securities category.
- Shares are now available for trading on both BSE and NSE.
- Kotak Mahindra Capital co-led Molbio Diagnostics’ IPO as book-running manager.
- Kfin Technologies served as registrar for the Molbio Diagnostics offering.
How Retail Investors Responded to Both Offerings
Retail participation differed noticeably between the two NSE IPO offerings this month. Dhoot Transmission’s retail category was subscribed 12.96 times by the close of bidding. Non-institutional investors showed even stronger appetite, subscribing that portion 49.80 times over. This broad-based demand across categories often signals healthier long-term listing performance.
What Analysts Are Watching Next
Analysts note both NSE IPO debuts reflect a healthy primary market environment currently. Dhoot Transmission’s stronger institutional demand translated directly into its bigger listing-day gain. Molbio Diagnostics’ diversified diagnostic portfolio offers a different, more defensive growth story longer-term.
Investors should watch whether both stocks hold these gains through the coming week. Broader IPO market momentum will likely depend on how these debuts perform ahead.
Disclaimer:
The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)